Abstract :
The nuclear hormone receptor family has three distinct subtypes: PPAR-?, PPAR-β/?, and PPAR-?.Peroxisome proliferator activated receptor (PPARs)are genes that are activated by compounds. Triglycerides levels are reduced and the balance of energy is maintained when PPAR-? is stimulated. Fibrates are compounds that act as agonists for the PPAR, and have been used to treat dyslipidemia because of their effects on reducing triglycerides and increasing HDL-C (high density lipoprotein cholesterol). Recent research has also demonstrated that PPAR- agonist have anti-inflammatory and anti- thrombotic properties in the arterial wall. The stimulation of PPAR-β/? increases the efficiency of the metabolism of fatty acids, it also maintains physical stamina and is considered the primary option for dealing with metabolic disorders. The activation of PPAR-? promotes glucose metabolism and increase the sensitivity of insulin. Today, it is commonly understood that the dysregulated IGF systems is associated with the developmental and progression of various human cancers. As a result, the balance of energy and metabolic processes is primarily determined by the nuclear receptors of the PPAR family. The current state of knowledge regarding the beneficial and detrimental effects of PPAR agonists on various diseases, including dyslipidemia, diabetes, adipocyte inflammation, cancer, and obesity is the subject of this review.
Keyword :
Peroxisome Proliferator Activated Receptor, Diabetes, Dyslipidemia, Obesity